About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025

Company to highlight continuous innovation, pharma partnership, and commitment to advancing cancer care through poster presentations and booth demos

Thermo Fisher Scientific, the world leader in serving science, will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – are improving access to targeted cancer therapies.

By advancing NGS technologies that prioritize speed, accuracy, and accessibility, the company, through its clinical sequencing business, is helping to ensure that patients in all care settings benefit from the latest innovations. This year marks a significant milestone for Thermo Fisher: a decade of pharma partnership in NGS companion diagnostics development and commercialization, supporting new drug launches globally with decentralized in-country CDx solution.

This commitment extends to its clinical research capabilities. Over the past five years, Thermo Fisher has supported more than 750 hematology and oncology clinical trials, involving over 175,000 patients at more than 35,000 sites in over 100 countries. Through its PPD™ clinical research business, the company takes a patient-centered approach to trial design and execution, ensuring that studies are not only scientifically rigorous but also more accessible and inclusive.

“Reflecting on the last decade of partnership with pharmaceutical companies and their therapeutic innovations, we’re proud to continue our legacy as a trusted partner and celebrate the impact these collaborations have had on expanding access to precision cancer care,” said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. “Behind every test is a patient waiting for answers. That’s what drives us – equipping clinicians with fast, reliable insights so they can make confident, timely treatment decisions that change lives.”

Davy will deliver opening remarks at the Canadian Evening at ASCO 2025, hosted by Breast Cancer Canada. Held Friday, May 30, at the Marriott Marquis Chicago, this event brings together researchers, clinicians, advocates, and industry leaders to celebrate progress in cancer research.

Research and Abstract Highlights at ASCO 2025

At ASCO 2025, researchers from Thermo Fisher and its customers will present new data on precision oncology, including:

  • Assessment of Homologous Recombination Deficiency and BRCA Status (Abstract 3130, Poster presentation) - evaluates a decentralized NGS assay for identifying HRD and BRCA mutations in ovarian cancer.
  • Combined Genomic Profiling of cfDNA and ctDNA – demonstrates how dual analysis of cfDNA and ctcDNA using a prostate cancer-specific panel can provide complementary molecular insights.
  • Association between Targeted Therapy and Survival in Patients with AML (Abstract e23283 in collaboration with EVERSANA) - analyzes real-world data showing improved survival in high-risk MDS patients receiving targeted therapies based on genetic mutations.

Attendees can connect with Thermo Fisher experts at booth #12049 to learn more about how the company supports oncology programs from research through commercialization.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.